CLL-IPI
| . | Score . | 5-y survival, % . |
|---|---|---|
| Biomarker | ||
| Age, y | ||
| ≤65 | 0 | |
| >65 | 1 | |
| Stage | ||
| Rai 0/Binet A | 0 | |
| Rai I-IV/Binet B-C | 1 | |
| β2-microglobulin, mg/L | ||
| ≤3.5 | 0 | |
| >3.5 | 2 | |
| IGHV | ||
| Mutated | 0 | |
| Unmutated | 2 | |
| TP53 | ||
| No abnormalities | 0 | |
| Deletion and/or mutation | 4 | |
| Risk group | ||
| Low risk | 0-1 | 93 |
| Intermediate risk | 2-3 | 79 |
| High risk | 4-6 | 63 |
| Very-high risk | 7-10 | 23 |
| . | Score . | 5-y survival, % . |
|---|---|---|
| Biomarker | ||
| Age, y | ||
| ≤65 | 0 | |
| >65 | 1 | |
| Stage | ||
| Rai 0/Binet A | 0 | |
| Rai I-IV/Binet B-C | 1 | |
| β2-microglobulin, mg/L | ||
| ≤3.5 | 0 | |
| >3.5 | 2 | |
| IGHV | ||
| Mutated | 0 | |
| Unmutated | 2 | |
| TP53 | ||
| No abnormalities | 0 | |
| Deletion and/or mutation | 4 | |
| Risk group | ||
| Low risk | 0-1 | 93 |
| Intermediate risk | 2-3 | 79 |
| High risk | 4-6 | 63 |
| Very-high risk | 7-10 | 23 |